Cargando…
Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease
Inflammatory bowel disease (IBD) is an idiopathic intestinal inflammatory disease that comprises ulcerative colitis (UC) and Crohn’s disease (CD). IBD involves the ileum, rectum, and colon, and common clinical manifestations of IBD are diarrhea, abdominal pain, and even bloody stools. Currently, non...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580650/ https://www.ncbi.nlm.nih.gov/pubmed/31236131 http://dx.doi.org/10.1186/s13020-019-0245-x |
_version_ | 1783428064108085248 |
---|---|
author | Gao, Caifang Liu, Lijuan Zhou, Yangyang Bian, Zhaoxiang Wang, Shengpeng Wang, Yitao |
author_facet | Gao, Caifang Liu, Lijuan Zhou, Yangyang Bian, Zhaoxiang Wang, Shengpeng Wang, Yitao |
author_sort | Gao, Caifang |
collection | PubMed |
description | Inflammatory bowel disease (IBD) is an idiopathic intestinal inflammatory disease that comprises ulcerative colitis (UC) and Crohn’s disease (CD). IBD involves the ileum, rectum, and colon, and common clinical manifestations of IBD are diarrhea, abdominal pain, and even bloody stools. Currently, non-steroidal anti-inflammatory drugs, glucocorticoids, and immunosuppressive agents are used for the treatment of IBD, while their clinical application is severely limited due to unwanted side effects. Chinese medicine (CM) is appealing more and more attention and investigation for the treatment of IBD owing to the potent anti-inflammation pharmacological efficacy and high acceptance by patients. In recent years, novel drug delivery systems are introduced apace to encapsulate CM and many CM-derived active constituents in order to improve solubility, stability and targeting ability. In this review, advanced drug delivery systems developed in the past and present to deliver CM for the treatment of IBD are summarized and future directions are discussed. |
format | Online Article Text |
id | pubmed-6580650 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65806502019-06-24 Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease Gao, Caifang Liu, Lijuan Zhou, Yangyang Bian, Zhaoxiang Wang, Shengpeng Wang, Yitao Chin Med Review Inflammatory bowel disease (IBD) is an idiopathic intestinal inflammatory disease that comprises ulcerative colitis (UC) and Crohn’s disease (CD). IBD involves the ileum, rectum, and colon, and common clinical manifestations of IBD are diarrhea, abdominal pain, and even bloody stools. Currently, non-steroidal anti-inflammatory drugs, glucocorticoids, and immunosuppressive agents are used for the treatment of IBD, while their clinical application is severely limited due to unwanted side effects. Chinese medicine (CM) is appealing more and more attention and investigation for the treatment of IBD owing to the potent anti-inflammation pharmacological efficacy and high acceptance by patients. In recent years, novel drug delivery systems are introduced apace to encapsulate CM and many CM-derived active constituents in order to improve solubility, stability and targeting ability. In this review, advanced drug delivery systems developed in the past and present to deliver CM for the treatment of IBD are summarized and future directions are discussed. BioMed Central 2019-06-17 /pmc/articles/PMC6580650/ /pubmed/31236131 http://dx.doi.org/10.1186/s13020-019-0245-x Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Gao, Caifang Liu, Lijuan Zhou, Yangyang Bian, Zhaoxiang Wang, Shengpeng Wang, Yitao Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease |
title | Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease |
title_full | Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease |
title_fullStr | Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease |
title_full_unstemmed | Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease |
title_short | Novel drug delivery systems of Chinese medicine for the treatment of inflammatory bowel disease |
title_sort | novel drug delivery systems of chinese medicine for the treatment of inflammatory bowel disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580650/ https://www.ncbi.nlm.nih.gov/pubmed/31236131 http://dx.doi.org/10.1186/s13020-019-0245-x |
work_keys_str_mv | AT gaocaifang noveldrugdeliverysystemsofchinesemedicineforthetreatmentofinflammatoryboweldisease AT liulijuan noveldrugdeliverysystemsofchinesemedicineforthetreatmentofinflammatoryboweldisease AT zhouyangyang noveldrugdeliverysystemsofchinesemedicineforthetreatmentofinflammatoryboweldisease AT bianzhaoxiang noveldrugdeliverysystemsofchinesemedicineforthetreatmentofinflammatoryboweldisease AT wangshengpeng noveldrugdeliverysystemsofchinesemedicineforthetreatmentofinflammatoryboweldisease AT wangyitao noveldrugdeliverysystemsofchinesemedicineforthetreatmentofinflammatoryboweldisease |